The obesity treatment landscape is rapidly evolving as pharmaceutical research advances toward therapies designed to deliver meaningful weight reduction, metabolic improvements, and greater treatment convenience. Growing investment in GLP-1 therapies and multi-receptor agonists is driving important obesity drug updates, while an expanding pipeline is creating new possibilities for patients...